{"name":"BioSyngen Pte Ltd","slug":"biosyngen-pte-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Second dose","genericName":"Second dose","slug":"second-dose","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Second dose","genericName":"Second dose","slug":"second-dose","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxOdUlra1YtSmhrSmtHY0xFTmVVLXhoM3ZpRHdwTG91Wm5XeU92SlJ3UkYyZGNuOWNiWnFYbW82RElzbTA3NGdEcDRuWkRXS3J2RWlEcXl5MUJKWVpQUjJ3aDVoTjhRZjZtT1ROMWRJZDNXY2p1NGJhak92dGtXeGJWUGFMVzVYYWwwUm1Yd3YwMjVGU3N4bC1meDNEUDFlVmhkOTA5WUlGM3Etd3Q5YnZleWJsSndvdDdUejlId2tpTjVoZnYzQ19sSjdNX3lEeFN1TDczajRDNjhYWWFBMFpxblJHU05TWjdOOEZfUS1XT0hOMDVtazZmdG1SMk8?oc=5","date":"2021-12-29","type":"pipeline","source":"PR Newswire Asia","summary":"Biosyngen Pte Ltd launched biological production base for commercialization of immune cell therapeutics in China - PR Newswire Asia","headline":"Biosyngen Pte Ltd launched biological production base for commercialization of immune cell therapeutics in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQMGpXcGtaV0RieGx3ckhiMXdmM0pGLWMtWDZfSFRoc3BGcy1FS0phT0wtMlZBdzZNUGo4ZHhyLUNLR2drYThobDNreDNTLWk5LW1wQXIxd3ZVUzBtVmI0TUhjWmh2aHRvNlUzNEhrUDA0cGw4OGhMTlJtTkh5cnEyM3JmcTNTN2l3a1c3dG9fZ0lJTXBJdnNrb0JHbGtPakdlNFc2SXRwX0NMazNU?oc=5","date":"2021-10-21","type":"pipeline","source":"BioPharma APAC","summary":"Singapore-based Biosyngen receives 500 million yuan in investment - BioPharma APAC","headline":"Singapore-based Biosyngen receives 500 million yuan in investment","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}